We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amicus to Delay Amigal NDA Filing Per FDA Remarks
Amicus to Delay Amigal NDA Filing Per FDA Remarks
June 21, 2013
Amicus Therapeutics says it is holding off filing an NDA for its orphan drug Amigal to treat Fabry disease until it analyzes data from a second Phase III study as recommended by the FDA.